Original source
Scientific Advice on Cannabidiol (CBD) (CAS/EC No. 13956-29- 1/ 689-176-3) used in cosmetic products
- Official date
- 2026-04-24
Unlock the official file
Business Impact stays free. Paid plans unlock the original source, official text, and Regulatory Details — plus Workbench and Verify credits.
The SCCS Scientific Advice (SCCS/1685/25) assesses the maximum safe concentration of CBD in cosmetic products and the safe level of THC as a contaminant. It concludes that CBD is safe up to 0.19% in dermal and oral cosmetic products, whether used separately or in combination, and that THC impurities are safe up to 0.00025% in these products. The assessment is based on pure CBD and does not consider inhalation exposure. The advice was adopted on 26 March 2026 and published on 24 April 2026, following a request from the European Commission.
The SCCS has issued final scientific advice on the safe use of Cannabidiol (CBD) in cosmetic products. It concludes that CBD is safe at concentrations up to 0.19% in dermal and oral cosmetic products, and that THC impurities are safe up to 0.00025% in these products. This advice is based on limited data and does not cover inhalation exposure.
Official text
English translation — the official-language text prevails
Conclusion of the opinion:
1. Taking under consideration the information/data submitted via the respective call for data, the SCCS is requested: (a) to assess the maximum concentration of Cannabidiol that is considered safe when used in cosmetic products Based on the limited available data, the SCCS considers CBD safe when used at concentrations up to 0.19% in dermal cosmetic products and oral cosmetic products – whether used separately or in combination. (b) to identify the maximum safe level of Delta-9-tetrahydrocannabinol (THC) present as a contaminant in Cannabidiol preparations The SCCS considers the presence of THC impurities as safe at concentrations up to 0.00025% in dermal and oral cosmetic products – whether used separately or in combination. The SCCS acknowledges that the current evaluation may have some limitations because of the paucity of data/information received from a few respondents to the Commission’s Call for data. These limitations can be addressed as and when adequate data / information can be made available by interested Applicants.
2. Does the SCCS have any further scientific concerns with regard to the use of CBD and the possible non-intended presence at trace levels of other cannabinoids, including THC, in cosmetic products? This assessment is based only on the safety of pure CBD. This Scientific Advice does not consider the use of CBD in cosmetic products that may lead to exposure of the end-user’s lungs by inhalation.